- Home
- ANGH vs TXMD Comparison
ANGH vs TXMD Comparison
Compare ANGH & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANGH | TXMD |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.1M | 25.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ANGH | TXMD |
|---|---|---|
| Price | $2.35 | $2.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 19.7K | ★ 102.0K |
| Earning Date | 04-30-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | ★ $96,736,848.00 | $2,796,000.00 |
| Revenue This Year | N/A | $427.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $92.75 |
| Revenue Growth | ★ 85.06 | 75.19 |
| 52 Week Low | $2.25 | $0.72 |
| 52 Week High | $7.60 | $2.95 |
Technical Indicators
Market Signals| Indicator | ANGH | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 36.43 | 56.98 |
| Support Level | $2.29 | $2.12 |
| Resistance Level | $2.44 | $2.45 |
| Average True Range (ATR) | 0.18 | 0.23 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 7.90 | 39.08 |
Price Performance
Historical ComparisonAbout ANGH Anghami Inc.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. It generates the majority of its revenue from subscriptions.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.